tetano
Editor, Senior Moderator
Drug Deliv Transl Res
. 2021 Feb 15.
doi: 10.1007/s13346-021-00927-4. Online ahead of print.
Fabrication of microneedle patches with lyophilized influenza vaccine suspended in organic solvent
Yoo Chun Kim[SUP] 1 [/SUP], Jeong Woo Lee[SUP] 1 [/SUP], E Stein Esser[SUP] 2 [/SUP], Haripriya Kalluri[SUP] 1 [/SUP], Jessica C Joyce[SUP] 3 [/SUP], Richard W Compans[SUP] 2 [/SUP], Ioanna Skountzou[SUP] 2 [/SUP], Mark R Prausnitz[SUP] 4 5 [/SUP]
Affiliations
Abstract
Skin vaccination by microneedle (MN) patch simplifies the immunization process to increase access to vaccines for global health. Lyophilization has been widely used to stabilize vaccines and other biologics during storage, but is generally not compatible with the MN patch manufacturing processes. In this study, our goal was to develop a method to incorporate lyophilized inactivated H1N1 influenza vaccine into MN patches during manufacturing by suspending freeze-dried vaccine in anhydrous organic solvent during the casting process. Using a casting formulation containing chloroform and polyvinylpyrrolidone, lyophilized influenza vaccine maintained activity during manufacturing and subsequent storage for 3 months at 40 ?C. Influenza vaccination using these MN patches generated strong immune responses in a murine model. This manufacturing process may enable vaccines and other biologics to be stabilized by lyophilization and administered via a MN patch.
Keywords: Lyophilized influenza vaccine; Microarray patch; Microfabrication; Microneedle patch; Skin vaccination; Vaccine stability.
. 2021 Feb 15.
doi: 10.1007/s13346-021-00927-4. Online ahead of print.
Fabrication of microneedle patches with lyophilized influenza vaccine suspended in organic solvent
Yoo Chun Kim[SUP] 1 [/SUP], Jeong Woo Lee[SUP] 1 [/SUP], E Stein Esser[SUP] 2 [/SUP], Haripriya Kalluri[SUP] 1 [/SUP], Jessica C Joyce[SUP] 3 [/SUP], Richard W Compans[SUP] 2 [/SUP], Ioanna Skountzou[SUP] 2 [/SUP], Mark R Prausnitz[SUP] 4 5 [/SUP]
Affiliations
- PMID: 33590465
- DOI: 10.1007/s13346-021-00927-4
Abstract
Skin vaccination by microneedle (MN) patch simplifies the immunization process to increase access to vaccines for global health. Lyophilization has been widely used to stabilize vaccines and other biologics during storage, but is generally not compatible with the MN patch manufacturing processes. In this study, our goal was to develop a method to incorporate lyophilized inactivated H1N1 influenza vaccine into MN patches during manufacturing by suspending freeze-dried vaccine in anhydrous organic solvent during the casting process. Using a casting formulation containing chloroform and polyvinylpyrrolidone, lyophilized influenza vaccine maintained activity during manufacturing and subsequent storage for 3 months at 40 ?C. Influenza vaccination using these MN patches generated strong immune responses in a murine model. This manufacturing process may enable vaccines and other biologics to be stabilized by lyophilization and administered via a MN patch.
Keywords: Lyophilized influenza vaccine; Microarray patch; Microfabrication; Microneedle patch; Skin vaccination; Vaccine stability.